FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory (CRDAC) Meeting Date: 13 September 2012

First Page		Document Content
Medical statistics Lixivaptan Electrolyte disturbances Organochlorides Design of experiments Hyponatremia Clinical trial Vasopressin receptor antagonist Tolvaptan Medicine Health Epidemiology		FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory (CRDAC) Meeting Date: 13 September 2012 Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 4,36 MB Share Document on Facebook

	FDA Briefing Document for the Cardiovascular and Renal Drugs Advisory (CRDAC) Meeting Date: 13 September 2012 DocID: EgJl - View Document
	Cardiokine Biopharma, LLC Lixivaptan Briefing Document NDA 203,009 Page 1 of 61 DocID: DdpY - View Document
	The Targeting Acute Congestion with Tolvaptan In Congestive Heart Failure Study TACTICS-HF Felker GM, Adams KF, Cole RT, Patel CB, Egnaczyk G, Mentz RJ, Fiuzat M, and O’Connor CM on behalf of the TACTICS Investigators DocID: tk1g - View Document
	ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS DocID: 3jWY - View Document